Friday, October 19, 2018 11:12:55 AM
https://webfiles.thecse.com/investorx/CROP/1810180920275543.pdf?2L_qzHc4c_03CJU1k6z0DbrfJpnmURlc
This a double-edged sword. Obviously another 17M shares issued would result in about a 14% dilution to current shareholders.
On the other hand, exercise of ALL these warrants will result in about $6.9M (C) in cash for the company. Any cash received now, before revenues start flowing, should greatly reduce the need for future cash raises via warrants or common share issuances.
Also note that this early warrant exercise program is slated to end on Nov. 2, 2018. Why Nov. 2? Think about it.
P.S. The warrant exercise price is $.40 (C) which is currently equivalent to $.305 (US). Hence the reason CRXPF is currently trading around $.30 imo.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM